ReviewClinical infectious diseases : an official publication of the Infectious Diseases Society of America2017
Optimizing Research to Speed Up Availability of Pediatric Antiretroviral Drugs and Formulations.
Review in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Pediatric human immunodeficiency virus infection in the modern era: A systematic review of recent advances and their implications.Pediatric investigation · 2025Review
- Rapid Enzymatic Assay for Antiretroviral Drug Monitoring Using CRISPR-Cas12a-Enabled Readout.ACS synthetic biology · 2025Article
- Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination.Frontiers in immunology · 2024Review
- Novel Approaches to Postnatal Prophylaxis to Eliminate Vertical Transmission of HIV.Global health, science and practice · 2023Article
- Potential of Long-Acting Products to Transform the Treatment and Prevention of Human Immunodeficiency Virus (HIV) in Infants, Children, and Adolescents.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2022Article
- Viral Response among Early Treated HIV Perinatally Infected Infants: Description of a Cohort in Southern Mozambique.Healthcare (Basel, Switzerland) · 2022Article
- Real-Life Feasibility of HIV Drug Resistance Testing Using Dried Filter Analytes in Kenyan Children and Adolescents Living with HIV.Microbiology spectrum · 2022Article
- Ensuring continued progress for development of COVID-19 therapeutics in children.Pediatric research · 2021Article
- Are we there yet? 40 years of successes and challenges for children and adolescents living with HIV.Journal of the International AIDS Society · 2021Article
- Antiretroviral Therapy in Children and Adolescents: A Look Into Modern Single Tablet Regimens.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2021Article
- The HIV drug optimization agenda: promoting standards for earlier investigation and approvals of antiretroviral drugs for use in adolescents living with HIV.Journal of the International AIDS Society · 2020Article
- HIV and antiretroviral therapy-related fat alterations.Nature reviews. Disease primers · 2020Review
- Inclusion of pregnant women in antiretroviral drug research: what is needed to move forwards?Journal of the International AIDS Society · 2019Article
- Review
- Optimizing Pediatric Dosing Recommendations and Treatment Management of Antiretroviral Drugs Using Therapeutic Drug Monitoring Data in Children Living With HIV.Therapeutic drug monitoring · 2019Review
- Propelling the Pediatric HIV Therapeutic Agenda With Science, Innovation, and Collaboration.Journal of acquired immune deficiency syndromes (1999) · 2018Article
- Optimizing Clinical Trial Design to Maximize Evidence Generation in Pediatric HIV.Journal of acquired immune deficiency syndromes (1999) · 2018Article
- A broader look at adolescents with perinatal HIV.Nature · 2018Article
- Shortening the decade-long gap between adult and paediatric drug formulations: a new framework based on the HIV experience in low- and middle-income countries.Journal of the International AIDS Society · 2018Article
Corrections and comments
- Erratum issuedErratum.2017
Authors and funding
14 authors.
Funding
Abstract
Globally 1.8 million children are living with human immunodeficiency virus (HIV), yet only 51% of those eligible actually start treatment. Research and development (R&D) for pediatric antiretrovirals (ARVs) is a lengthy process and lags considerably behind drug development in adults. Providing safe, effective, and well-tolerated drugs for children remains critical to ensuring scale-up globally. We review current approaches to R&D for pediatric ARVs and suggest innovations to enable simplified, faster, and more comprehensive strategies to develop optimal formulations. Several approaches could be adopted, including focusing on a limited number of prioritized formulations and strengthening existing partnerships to ensure that pediatric investigation plans are developed early in the drug development process. Simplified and more efficient mechanisms to undertake R&D need to be put in place, and financing mechanisms must be made more sustainable. Lessons learned from HIV should be shared to support progress in developing pediatric formulations for other diseases, including tuberculosis and viral hepatitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.